Corcept Therapeutics, Inc. (NASDAQ:CORT)

no big expections in near term

After a lot of bad luck, I think this stock is finally going to make a rally.

This stock may be a worth less than 50 cents in a year. The drug the FDA is currently reviewing, Corlux, has the same active ingredient as the pill that is taken to eliminate early pregnancy. I don't see the FDA allowing such a drug to be distributed when Corlux would only benefit about 5-10 thousand people anyway. The rest of their pipeline is dependent on the same active ingredient.

March 27, 2008 12:44 PM EDT

Corcept Therapeutics Inc. (Nasdaq: CORT) Director, Joseph Cook, bought 176,522 on 3/25 at $2.77, bringing his stake to 1,656,360 shares. In addition, Director, David Mahoney, bought 70,609 shares on 3/25 at $2.77, bringing his stake to 636,547 shares.

Corcept Therapeutics Incorporated develops drugs for the treatment of severe psychiatric and metabolic diseases. [LJ]

Health, health, health! One cannot go wrong with health. And the more they specialize and branch out, the better the prospects for these companies.

Since the inception of this stock, given it's highs and lows, the trend shows the stock outperforming the S&P 500.